Mindavit (Cholecalciferol Concentrate (Powder Form))

After oral intake, cholecalciferol is metabolized in the liver to 25‑hydroxyvitamin D and then in the kidney to the active hormone 1,25‑dihydroxyvitamin D. This active form binds to nuclear vitamin D receptors, increasing transcription of calcium‑binding proteins that boost intestinal calcium and phosphate absorption, essential for bone health.

The appropriate dose of Mindavit is determined by a qualified prescriber based on the patient’s serum vitamin D level, age, weight, and clinical condition. Dosage may vary from a single loading dose to daily maintenance amounts, and should always follow the healthcare professional’s recommendation.

Safety data for cholecalciferol in pregnancy and lactation are limited. While vitamin D is essential for fetal development, the prescriber should evaluate the risk‑benefit ratio and may recommend a dose that aligns with established prenatal guidelines. Women should consult their healthcare provider before use.

To order Mindavit, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mindavit provides cholecalciferol in a powder concentrate, which can be reconstituted for flexible dosing. Compared with ergocalciferol (vitamin D2) or pre‑filled tablets, cholecalciferol generally offers higher potency and longer half‑life, making it a preferred choice for sustained correction of deficiency.

Mindavit should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and direct light. Keep the container tightly closed and avoid exposure to extreme heat or humidity to maintain product stability.

Mindavit is supplied as a powder concentrate intended for oral use. The powder can be mixed with a small amount of water, juice, or soft food and taken with or without meals, following the dosage instructions provided by the prescriber.

The most serious risks involve excessive vitamin D intake leading to hypercalcemia, which can cause nausea, vomiting, weakness, kidney stones, and cardiac arrhythmias. Patients should have serum calcium monitored regularly, especially when high doses are prescribed.

Mindavit is contraindicated in individuals with known hypercalcemia, severe renal impairment, or disorders such as sarcoidosis or other granulomatous diseases that predispose to abnormal vitamin D metabolism. Anyone with these conditions should discuss alternatives with their healthcare provider.